within Pharmacolibrary.Drugs.N_NervousSystem.N05A_Antipsychotics.N05AX14_Iloperidone;

model Iloperidone
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.96,
    Cl = 1.0277777777777777e-05,
    adminDuration = 600,
    adminMass = 12 / 1000000,
    adminCount = 1,
    Vd = 0.377,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.010666666666666666,
    Tlag = 19.8,
    Vdp = 0.074,
    k12 = 1.5750000000000003e-05,
    k21 = 1.5750000000000003e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Iloperidone</td></tr><tr><td>ATC code:</td><td>N05AX14</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>12</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>377</td><td>L</td></tr>
    <tr><td>clearance:</td><td>37</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Iloperidone is an atypical antipsychotic medication primarily used for the treatment of schizophrenia in adults. It acts as an antagonist at dopamine D2 and serotonin 5-HT2A receptors and is approved for use in several countries, including the United States.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers following single and multiple oral dose administration of iloperidone.</p><h4>References</h4><ol><li><p>Crabtree, BL, &amp; Montgomery, J (2011). Iloperidone for the management of adults with schizophrenia. <i>Clinical therapeutics</i> 33(3) 330–345. DOI:<a href=\"https://doi.org/10.1016/j.clinthera.2011.03.006\">10.1016/j.clinthera.2011.03.006</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21600386/\">https://pubmed.ncbi.nlm.nih.gov/21600386</a></p></li><li><p>Rado, J, &amp; Janicak, PG (2012). Pharmacological and clinical profile of recently approved second-generation antipsychotics: implications for treatment of schizophrenia in older patients. <i>Drugs &amp; aging</i> 29(10) 783–791. DOI:<a href=\"https://doi.org/10.1007/s40266-012-0009-0\">10.1007/s40266-012-0009-0</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23018584/\">https://pubmed.ncbi.nlm.nih.gov/23018584</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N05AX14 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Iloperidone;
